Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 19/20 | 1.00 |
| ▸ | MMP13 | P45452 | 14/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067998 | 0.93 | MMP12 (0.86) | MMP12MMP13 | |
| SCHEMBL21068000 | 0.93 | MMP12 (0.86) | MMP12MMP13 | |
| SCHEMBL3079447 | 0.86 | MMP12 (0.89) | MMP12MMP13 | |
| SCHEMBL3088136 | 0.83 | MMP12 (0.70) | MMP12MMP13ADAMTS4 | |
| SCHEMBL4010999 | 0.83 | MMP12 (1.00) | MMP12MMP13 | |
| SCHEMBL4014496 | 0.83 | MMP12 (1.00) | MMP12MMP13 | |
| SCHEMBL3073121 | 0.83 | MMP12 (0.70) | MMP12MMP13 | |
| SCHEMBL3067254 | 0.82 | MMP12 (0.72) | MMP12MMP13ADAMTS4 | |
| SCHEMBL3080118 | 0.82 | MMP12 (0.72) | MMP12MMP13ADAMTS4 | |
| SCHEMBL4013634 | 0.82 | MMP12 (1.00) | MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2003-02-13 | — | — | US | claimed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| US-6906092-B2 | Method of inhibiting matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6620835-B2 | Sulfonamide-substituted benzothiophenes (that may be oxidized), carbazoles, fluorenes and fluorenones | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2003-02-13 | — | — | US | disclosed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | MMP12 3/4885MMP13 11/4885ADAMTS4 26/4885 |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | MMP12 3/4885MMP13 11/4885ADAMTS4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.